Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07481708 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of the Effect of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-041)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT07481708 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 30 participants.
The verdict
NCT07481708, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The goal of this study is to learn what happens to enlicitide (MK-0616) in a healthy person's body over time (pharmacokinetic or PK study). Researchers also want to learn about the safety of enlicitide and if people tolerate it.
Interventions
- DRUG Enlicitide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-03-23 |
| Est. Completion | 2026-05-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07481708
The ClinicalTrials.gov registry entry for NCT07481708 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enlicitide is the first listed.
NCT07481708 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07481708 about?
NCT07481708 is a clinical study titled "A Clinical Study of the Effect of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-041)". The goal of this study is to learn what happens to enlicitide (MK-0616) in a healthy person's body over time (pharmacokinetic or PK study). Researchers also want to learn about the safety of enlicitide and if people tolerate it.
What is the current status of trial NCT07481708?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-03-23. Estimated completion is 2026-05-25.
What interventions are being tested in trial NCT07481708?
The interventions under investigation include: Enlicitide (DRUG).
Who is sponsoring clinical trial NCT07481708?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.